APOE and atherosclerosis: Notably, the progression of atherosclerosis was markedly reduced in Frs2αSMCKO/Apoe−/− mice compared to Apoe−/− controls: By 8 weeks, there was a 43% decrease in the total aorta plaque size (5.57% in Apoe−/− versus 3.16% in Frs2αSMCKO/Apoe−/−) (Fig EV5B) and by 16 weeks 50% decrease (17.04% in Apoe−/− versus 8.47% in Frs2αSMCKO/Apoe−/−) (Fig 7B).